A systematic review of commercial weight loss programmes' effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus.

Autor: Chaudhry ZW; The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Doshi RS; The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Mehta AK; The Johns Hopkins Bayview Medical Center, Baltimore, MD, USA., Jacobs DK; The University of Maryland School of Medicine, Baltimore, MD, USA., Vakil RM; The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.; Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA., Lee CJ; The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Bleich SN; The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Kalyani RR; The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Clark JM; The Johns Hopkins University School of Medicine, Baltimore, MD, USA.; The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.; The Welch Center for Prevention, Epidemiology, Prevention, and Clinical Research, Baltimore, MD, USA., Gudzune KA; The Johns Hopkins University School of Medicine, Baltimore, MD, USA.; The Welch Center for Prevention, Epidemiology, Prevention, and Clinical Research, Baltimore, MD, USA.
Jazyk: angličtina
Zdroj: Obesity reviews : an official journal of the International Association for the Study of Obesity [Obes Rev] 2016 Aug; Vol. 17 (8), pp. 758-69. Date of Electronic Publication: 2016 May 26.
DOI: 10.1111/obr.12423
Abstrakt: Objective: We examined the glycemic benefits of commercial weight loss programmes as compared with control/education or counselling among overweight and obese adults with and without type 2 diabetes mellitus (T2DM).
Methods: We searched MEDLINE, Cochrane Database of Systematic Reviews, and references cited by individual programmes. We included randomized controlled trials of ≥12 weeks duration. Two reviewers extracted information on study design, population characteristics, interventions, and mean changes in haemoglobin A1c and glucose.
Results: We included 18 randomized controlled trials. Few trials occurred among individuals with T2DM. In this population, Jenny Craig reduced A1c at least 0.4% more than counselling at 12 months, Nutrisystem significantly reduced A1c 0.3% more than counselling at 6 months, and OPTIFAST reduced A1c 0.3% more than counselling at 6 months. Among individuals without T2DM, few studies evaluated glycemic outcomes, and when reported, most did not show substantial reductions.
Discussion: Few trials have examined whether commercial weight loss programmes result in glycemic benefits for their participants, particularly among overweight and obese individuals without T2DM. Jenny Craig, Nutrisystem and OPTIFAST show promising glycemic lowering benefits for patients with T2DM, although additional studies are needed to confirm these conclusions. © 2016 World Obesity.
(© 2016 World Obesity.)
Databáze: MEDLINE
Externí odkaz: